1. Home
  2. PRZO vs PPBT Comparison

PRZO vs PPBT Comparison

Compare PRZO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ParaZero Technologies Ltd.

PRZO

ParaZero Technologies Ltd.

HOLD

Current Price

$0.90

Market Cap

25.1M

Sector

N/A

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.71

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRZO
PPBT
Founded
2014
2010
Country
Israel
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1M
6.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
PRZO
PPBT
Price
$0.90
$0.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
461.3K
735.2K
Earning Date
08-28-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,007,440.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
80.42
N/A
52 Week Low
$0.53
$0.53
52 Week High
$3.16
$5.20

Technical Indicators

Market Signals
Indicator
PRZO
PPBT
Relative Strength Index (RSI) 25.41 42.65
Support Level $1.13 $0.67
Resistance Level $1.20 $0.87
Average True Range (ATR) 0.06 0.05
MACD -0.03 -0.01
Stochastic Oscillator 5.39 17.54

Price Performance

Historical Comparison
PRZO
PPBT

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: